Direction
Buy
Sell
Types
LMT Order
Price
QTY
Amount
--
TNGX Tango Therapeutics
6.600+0.430+6.97%
Close
01/31 16:00 ET
6.6000.0000.00%
Pre Mkt Price 02/01 04:21 ET
High
6.620
Open
6.240
Turnover
2.25M
Low
6.060
Pre Close
6.170
Volume
350.69K
Pre-Market
5D
1D
1W
1M
1Q
1Y
Price Forecast
News
Comment
Barclays Keeps Their Buy Rating on Tango Therapeutics (TNGX)
Loss-making Tango Therapeutics (NASDAQ:TNGX) Sheds a Further US$64m, Taking Total Shareholder Losses to 18% Over 1 Year
The simplest way to benefit from a rising market is to buy an index fund. Active investors aim to buy stocks that vastly outperform the market - but in the process, they risk under-performance. That
SVB Securities Reaffirms Their Buy Rating on Tango Therapeutics (TNGX)
12 Health Care Stocks Moving In Thursday's After-Market Session
GainersAkanda (NASDAQ:AKAN) stock increased by 28.2% to $0.36 during Thursday's after-market session. Akanda's trading volume hit 4.1 million shares by close, accounting for 474.8% of its average volu
Tango Therapeutics Provides Upcoming Milestones
Tango Therapeutics Announces FDA Clearance Of Investigational New Drug Application For TNG462
Tango Therapeutics Announces FDA Clearance Of Investigational New Drug Application For TNG462
Tango Therapeutics, Inc. (NASDAQ:TNGX) Short Interest Up 33.9% in December
Tango Therapeutics, Inc. (NASDAQ:TNGX – Get Rating) saw a significant increase in short interest in December. As of December 30th, there was short interest totalling 1,460,000 shares, an increase of
Reviewing Aurinia Pharmaceuticals (NASDAQ:AUPH) & Tango Therapeutics (NASDAQ:TNGX)
Aurinia Pharmaceuticals (NASDAQ:AUPH – Get Rating) and Tango Therapeutics (NASDAQ:TNGX – Get Rating) are both small-cap medical companies, but which is the superior investment? We will compare the tw
Tango Therapeutics (NASDAQ:TNGX) Trading Up 3.7%
Tango Therapeutics, Inc. (NASDAQ:TNGX – Get Rating) shares were up 3.7% during trading on Friday . The stock traded as high as $7.79 and last traded at $7.79. Approximately 651 shares changed hands d
We're Not Very Worried About Tango Therapeutics' (NASDAQ:TNGX) Cash Burn Rate
Company Overview
More
Tango Therapeutics, Inc. operates as a biotechnology company, which engages in discovering and delivering precision cancer medicines. Its primary program is TNG908, a protein arginine methyl transferase 5 inhibitor that is being developed as a treatment for cancers with MTAP deletions. The company was founded by Alan Ashworth, William G. Kaelin, Jr., Jose Baselga, and Antoni Ribas in 2017 and is headquartered in Cambridge, MA.
CEO： Dr. Barbara L. Weber, M.D.
Market： NASDAQ
Listing Date： 08/11/2021
Paper Trade
More
Hot List
TradeSearchNews
SymbolLatest price%Chg
Loading...
Watchlist
No Stock Yet